Severe congenital neutropenia is genetically heterogeneous. A majority of cases are attributed to autosomal dominant mutations (inherited or sporadic) in the gene encoding neutrophil elastase (ELA2) (Dale et al, 2000) . Other rare causative genes have recently been found, including mutations in HAX1 (Klein et al, 2007) , but the prevalence of mutations in these genes in the general SCN population has yet to be determined (Boxer & Newburger, 2007) .
Following the identification of disease-associated genes, an emerging clinical concern is to identify genotype-phenotype associations that might inform therapeutic decisions. The largest published studies addressing this question have presented clinical data for a total of 23 and 54 (Bellanne-Chantelot et al, 2004 ) SCN patients stratified according to the presence or absence of any mutation in ELA2. This report describes associations of ELA2 mutation status with responsiveness to G-CSF therapy and risk of MDS/ AML in a larger cohort of 82 North American and Australian patients on long-term G-CSF, prospectively followed in the Severe Chronic Neutropenia International Registry (SCNIR) (Dale et al, 2003) .
Patients, materials and methods

The Severe Chronic Neutropenia International Registry
We studied patients enrolled in the SCNIR who had been diagnosed with SCN by their treating haematologist and who had blood or fibroblast samples stored in the University of Washington repository serving SCNIR patients from North America or Australia. Each patient specifically had a diagnosis of SCN; those with a diagnosis of cyclic neutropenia, Shwachman-Diamond Syndrome, or other related disorder were excluded. The 82 SCN patients included here (from 104 with any available samples) were all those with sufficient DNA for ELA2 sequencing, irrespective of baseline ANC or clinical response to G-CSF. ELA2 mutation analysis was conducted using standard polymerase chain reaction methods, Big Dye terminator technology, and an ABI analyzer (Applied Biosystems, Foster City, CA, USA). Validated data on G-CSF dose, and results of complete blood cell counts, were extracted from the database created for a prior study (Rosenberg et al, 2006) .
Follow-up for occurrence of MDS/AML, bone marrow transplant (BMT), or death from bacterial sepsis or other causes was current up to October 12, 2006 for all patients. This study was conducted in accordance with the Declaration of Helsinki, under the auspices of the Human Subjects Committee of the University of Washington and other participating institutions. Patients provided informed consent for genetic studies. All statistical analyses were performed on anonymized samples.
Statistical methods
We used a generalized linear model for dose-response analysis. For analysis of leukaemia risk, BMT or death from sepsis or other causes were considered to be censoring events. We tested for differences in rates using an exact binomial test, and differences in cumulative incidence using Cox models and likelihood ratio tests. All statistical tests were two-sided. P < 0AE05 was significant.
Results
The 82 patients were all treated with G-CSF. Treatment was initiated between 1987 and 2000 at a median age of 24 months. Subsequently, the patients contributed 904 person-years of follow-up, during which time 20 transformed to MDS/AML. Median follow-up was 10 years, ranging from 0AE7 to 18AE4 years.
Fifty-two patients had ELA2 mutations (63%), and 30 patients had wild-type ELA2 (37%). A total of seven, five, four and three patients carried the Pro110Leu, Ser97Leu, Gly185Arg, Val72Met missense mutations respectively. The 33 remaining patients harboured 27 other mutations.
Patients with mutant ELA2 had 2AE8-fold [95% confidence interval (CI): 1AE4-5AE5-fold] higher mean ANC than patients with wild-type ELA2, after controlling for G-CSF dose. In patients with mutant ELA2, the mean ANC on treatment was close to or above the therapeutic target of 1AE5 · 10 9 cells/l at every dose level (Fig 1) . In contrast, patients with wild-type ELA2 reached the therapeutic target only if they responded to comparatively low doses of G-CSF. Among 52 patients with mutant ELA2, 14 (27%) eventually developed MDS/AML, compared with six (20%) of 30 patients with wild-type ELA2; the crude proportions transforming to MDS/AML were not significantly different (P = 0AE67). Controlling for years-on-G-CSF, there was no significant difference in the cumulative incidence of MDS/AML in patients with mutant versus wild-type ELA2 (P = 0AE96): the cumulative incidences at 15 years were 36% (mutant) and 25% (wildtype), with broad and overlapping confidence intervals (Fig 2) . In all patients combined, the cumulative incidence was 34% (95% CI: 19-46%) at 15 years.
We considered the effects of specific ELA2 mutations among the 52 patients with any mutation. Two preliminary findings emerged in exploratory analysis. First, the four patients with Gly185Arg had a particularly severe course. On treatment, ANC values were low despite high doses of G-CSF, and two patients maintained on comparatively high doses of 48 and 21 lg/kg/d G-CSF developed MDS/AML at 10AE1 and 15AE1 years. Second, no MDS/AML events were observed in seven patients with the Pro110Leu missense mutation or in five patients with the Ser97Leu missense mutation. The crude rate of MDS/AML was significantly lower in these 12 patients than in the 40 with any other ELA2 mutation (0 events in 153 person-years versus 14 events in 468 person-years, respectively, P = 0AE04).
Discussion
Our study is the largest to date of ELA2 mutations and clinical outcomes in SCN. It is well known that almost all SCN patients respond to G-CSF, but there is considerable heterogeneity in the dose of G-CSF required to obtain a haematological response. In this study, we observed that patients with mutant ELA2 usually responded with higher ANC values at lower doses of G-CSF than patients with wild-type ELA2. As an exception to this general trend, we observed a particularly severe course in the four patients in our study with the ELA2 mutation Gly185Arg, consistent with the report from the French Neutropenia Registry that also had four SCN patients with this mutation (Bellanne-Chantelot et al, 2004) .
Notwithstanding these differences in response to therapy, an important finding was that patients with or without mutations in ELA2 were at extraordinary risk of MDS/AML. Indeed, there was no significant difference in risk between the two groups. In all patients combined, the cumulative incidence of MDS/AML was 34% after 15 years on G-CSF.
We do not believe that selection or referral bias had a major impact on our analysis. Considering patients who enroled during the same calendar periods, we found no differences in the rates of loss-to-follow-up according to ELA2 mutation status (data not shown). Furthermore, the incidence of MDS/ AML was similar in the patients included here, compared to other SCN patients in the SCNIR who were not included. Together, these observations suggest that our analyses of MDS/ AML are statistically valid.
In contrast to our results, the French Neutropenia Registry reported a significantly reduced leukaemia risk in patients with wild-type ELA2, based on their observation that no patient with wild-type transformed (Bellanne-Chantelot et al, 2004) . Our study was larger, with 20 MDS/AML events versus three MDS/AML events, and one acute lymphoblastic leukaemia event in the French study. We attribute the divergent results to statistical heterogeneity, and possibly, genetic heterogeneity between ELA2 wild-type patients in the respective studies. Our results suggest that it is the marrow disorder that leads to leukaemia, not simply the presence of an ELA2 mutation, and leads to the prediction that patients with wild-type ELA2 who develop leukaemia may ultimately be found to harbour mutations in a number of other causative genes.
Although the average incidence of MDS/AML in our cohort was similar in patients with and without ELA2 mutations, exploratory analysis supports the concept that susceptibility to MDS/AML varies by mutation. The subgroup of SCN patients with the Gly185Arg missense mutation may be at increased risk, given our findings and the leukaemias in this group reported by the French Neutropenia Registry (BellanneChantelot et al, 2004) . In addition, in our data, SCN patients with the Pro110Leu or Ser97Leu missense mutations were at significantly decreased risk. Interestingly, these specific ELA2 mutations are among the limited number associated with both SCN and cyclic neutropenia (Horwitz et al, 2007) .
From the clinical perspective, SCN patients with a wide diversity of ELA2 mutations, and SCN patients without ELA2 mutations, have been observed to transform to leukaemia. Therefore, the average risk is extraordinarily high. Until more refined predictions are available, all SCN patients should be considered at high risk. Our data also suggest that patients Fig 2. Cumulative incidence of MDS/AML in patients with SCN, by ELA2 mutation status. Cumulative incidence, by years on G-CSF therapy, and 95% confidence intervals at selected years (error bars), in patients with mutant (black) and wild-type (blue) ELA2. The KaplanMeier actuarial method was used to estimate the cumulative incidence curves.
with wild-type ELA2 who do not respond to standard doses of G-CSF are comparatively unlikely to respond to high doses. These patients should be considered for early haematopoietic stem cell transplantation, because they may be at high risk of mortality from sepsis. It is now essential to develop new practice guidelines for SCN (Touw & Bontenbal, 2007) . These guidelines will need to carefully weigh the potential risks and benefits of G-CSF therapy versus transplantation, and specify the appropriate role and timing of genetic and molecular tests in counselling and decision-making.
